Wednesday, August 16, 2023 10:11:20 AM
If you compare it to other promising biotech firms at similar stage coupled with TAM for GBM then I think we ought to be at at least $3B market cap (once UK application is submitted/accepted and some guidance on other applications)….but then NWBO does not trade like other promising biotech firms…in fact, we ought to be closer to $2B market cap or more right now….you can blame it on MMs, hedge funds, etc…but I also put a lot of blame on the management as they are unable to execute quickly, build the trust, excitement, and importantly bring the right partners/investors on board….not to forget the history of this management where they have done nothing but lost investor money over the last 15 years!
If more of the same continues, the response on MAA submission/acceptance PR could be muted just like TLD and JAMA.
Regardless, I think we will be well under a $1 at MAA acceptance. It’s likely we are in the low .40 or high .30 cent range before we get any news. And a double from there in the best case scenario will put us at about .80 cents or thereabouts and then it could move down towards .50 cent range again with more waiting game.
If more of the same continues, the response on MAA submission/acceptance PR could be muted just like TLD and JAMA.
Regardless, I think we will be well under a $1 at MAA acceptance. It’s likely we are in the low .40 or high .30 cent range before we get any news. And a double from there in the best case scenario will put us at about .80 cents or thereabouts and then it could move down towards .50 cent range again with more waiting game.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
